TCR Therapy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

TCR Therapy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight’s, “TCR Therapy Pipeline Insight 2024” report provides comprehensive insights about 30+ companies and 100+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the TCR Therapy Pipeline Report

  • DelveInsight’s TCR Therapy pipeline report depicts a robust space with 30+ active players working to develop 100+ pipeline therapies for TCR Therapy treatment.
  • The leading TCR Therapy Companies working in the market include Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
  • Promising TCR Therapy Therapies in the various stages of development include TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.
  • May 2024:- TScan Therapeutics Inc.- A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors. TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules.
  • April 2024:- TCRCure Biopharma Ltd- A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma. Cervical cancer is the most common gynecologic malignant tumor. The occurrence and progression of cervical carcinoma is firmly relevant to HPV (Human papilloma virus) infection. Cancer cells infected by HPV expressing an HPV protein called E6. E6 is the main factors of HPV 16 carcinogenesis.

 

Request a sample and discover the recent advances in TCR Therapy @ TCR Therapy Pipeline Outlook Report

 

TCR Therapy Overview

The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

 

The signal transduction mechanism by which a T cell elicits this response upon contact with its unique antigen is termed T-cell activation (just as phototransduction is the term given to the signal transduction event by which photoreceptors elicits vision upon exposure to photons). There are myriad molecules involved in the complex biochemical process (called trans-membrane signaling) by which T-cell activation occurs. The most common mechanism for activation and regulation of molecules beneath the lipid bilayer is via reversible tyrosine phosphorylation by protein kinase/phosphatase.

 

TCR Therapy Emerging Drugs

 

  • IMC F106C: Immunocore

IMC-F106C is an ImmTAC targeting PRAME for patients with HLA-A02, which is expressed in approximately 40% of Western populations (United States, Canada, EU). In order to expand the potential of TCR therapy targeting PRAME, the Company is developing IMC-T119C, a first-in-class ImmTAC product candidate targeting a PRAME peptide presented by HLA-A24. HLA-24 is an HLA-type that is estimated to be present in 60% of people in Japan and 15-20% in Western populations. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of patients with 1L advanced, cutaneous melanoma.

 

  • GSK 3377794: GlaxoSmithKline

GSK 3377794 developed by GlaxoSmithKline is an investigational SPEAR T-cell receptor targeting NY-ESO-1. GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognizing with high affinity the tumor-specific antigen, NY-ESO. When the modified cells are re-infused into the patient, they recognize and kill tumor cells that express the NY-ESO antigen.

 

  • MDG 1011: MediGene AG

MDG1011 is a TCR-T immunotherapy directed against the tumor antigen PRAME (Preferentially expressed Antigen in Melanoma) and was manufactured to be administered in a single intravenous dose to patients suffering from relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM) who had previously undergone extensive pre-treatment with standard or experimental therapies. Currently the drug is in Phase I/II stage of clinical trial evaluation for the treatment of patients with High Risk Myeloid and Lymphoid Neoplasms.

 

  • TSC-100: TScan Therapeutics

TSC-100 is HA-1 and HA-2 specific TCR-T candidates directed at eliminating native blood cells, including residual cancer cells, in target-positive and HLA-A*02:01-positive patients undergoing hematopoietic cell transplantation (HCT). TSC-100 was identified using ReceptorScan from hundreds of millions of CD8+T cells. The therapies is designed to elicit an anti-tumor response in patients by targeting HA-1 or HA-2 minor antigens, which are present on malignant and normal blood cells of patients but not on any of the new, donor-derived blood cells.

 

Learn more about TCR Therapy in clinical trials @ TCR Therapy Drugs

 

TCR Therapy Therapeutics Assessment

There are approx. 30+ key TCR Therapy companies which are developing the therapies for TCR Therapy. The TCR Therapy companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore.

 

DelveInsight’s TCR Therapy pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Discover more about TCR Therapy in development @ TCR Therapy Clinical Trials

 

TCR Therapy Companies

Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.

 

TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

TCR Therapy Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

To know more about TCR Therapy, visit @ TCR Therapy Segmentation

 

Scope of the TCR Therapy Pipeline Report

  • Coverage- Global
  • TCR Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • TCR Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • TCR Therapy Companies- Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
  • TCR Therapy Therapies- TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.

 

For further information on the TCR Therapy Pipeline Therapeutics, reach out @ TCR Therapy Products Development

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. TCR-Therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. TCR-Therapy – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. IMC F106C: Immunocore
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GSK 3377794: GlaxoSmithKline
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TSC-100: TScan Therapeutics
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. TCR-Therapy Key Companies
  18. TCR-Therapy Key Products
  19. TCR-Therapy- Unmet Needs
  20. TCR-Therapy- Market Drivers and Barriers
  21. TCR-Therapy- Future Perspectives and Conclusion
  22. TCR-Therapy Analyst Views
  23. TCR-Therapy Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: